Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699190 · ClinicalTrials.gov registry record
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 236
- Enrollment target
NCT02699190: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT02699190 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 236 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02699190 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 236 participants
- Enrollment target
Study Summary
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes. While recent work has demonstrated that whole genome sequencing (WGS), has the potential to dramatically increase diagnostic efficiency, significant questions remain around the impact on downstream clinical management approaches versus standard diagnostic approaches.
Primary Outcome
The primary objective of this study is to evaluate changes in diagnostic status in the study cohort for patients who received Whole Genome Sequencing (WGS) as part of clinical care. Differences in diagnostic status will be measured at disclosure of initial results or disclosure of reanalyzed results.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2024-10-31 |
What the finished NCT02699190 record still lists
NCT02699190 is an observational study that tracks outcomes without assigning an intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02699190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02699190 about?
NCT02699190 is a clinical study titled "LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies". Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes. While recent work has demonstrated that whole genome sequencing (WGS), has the potential to d...
What is the current status of trial NCT02699190?
This trial is currently completed. The enrollment target is 236 participants. The study started on 2017-01-06. Estimated completion is 2024-10-31.
Who is sponsoring clinical trial NCT02699190?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI